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Abstract
The largest gene family in the mammalian genome, containing over 1000 coding sequences in
mice, is comprised of the olfactory receptor (OR) genes. Olfactory sensory neurons (OSNs)
express olfactory receptor genes in a monoallelic and monogenic fashion also referred to as
singular gene expression. There have been different studies trying to explain this singularity
phenomenon, however none are convincing. One hypothesis suggests that adenylyl cyclase 3
(Adcy 3) plays an important role in regulating singularity. However, there are several studies that
disprove this model. In order for an OR to be expressed in an OSN, the gene must first be
transcribed into an mRNA strand, the mRNA strand must then be translated, and the receptor must
be trafficked to the membrane. Before the mRNA can leave the nucleus, it is modified in several
different ways including an addition of a 5’ cap, removal of introns and the addition of a poly(a)
tail. mRNA strands can be generated with many different cap structures. The function of the 5’
cap is still not entirely known; however, it has been observed that caps are involved in stabilizing
the mRNA strand and preventing it from being degraded once outside the nucleus. Here we will
test if singularity is achieved through marking of the mRNA strand on or near the 5’ cap. I present
a theoretical experiment with three possible outcomes. After isolating mRNA extracted from
mouse olfactory epithelium, the 5’ UTR region will be selectively analyzed using liquid
chromatography—mass spectrometry to detect any modifications that indicate the strand is
marked. Our findings may lead us to propose a new model for the achievement of singularity by
OSNs.
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Introduction

The olfactory system is a powerful sensory system used for the detection of billions of
odors. It has evolved in order to allow organisms to differentiate between pleasant and unpleasant
odors, which are directly associated with the harmfulness of substances. The mouse olfactory
system is composed of about 1,000 different odorant receptor (OR) genes which are expressed in
different olfactory sensory neurons (OSNs) [1, 2]. These ORs are 7-transmembrane G-Protein
coupled receptors (GPCRs) and can bind odorants to communicate valuable information about the
environment to higher order structures within the brain [3]. The odorants bind to the ORs found in
the nasal cavity. The olfactory bulbs are the first relay station in the brain that process the
information generated by the bound odorant and lead to a behavioral response. This response
depends upon the interpretation of the bound odorant molecule. OSNs have been observed to
express ORs in singularity, meaning they express only one OR gene per cell. The fundamentals of
initiation or maintenance of this singularity are unknown.

Overview of the anatomy of the olfactory system
The olfactory system comprises the peripheral and the central olfactory systems. Both
systems work together such that the brain is able to recognize different odors. An odorant enters
the nostrils, reaching the nasal cavity. The walls within the nasal cavity are lined with mucus
containing metabolic enzymes [4]. These enzymes can break down the odorants, which are then
detected by the OSNs found in the epithelium [4]. This step is necessary for a subset of odorant
molecules to be detected. Once bound, odorants cause the OSNs to fire action potentials through
the olfactory nerve fiber which starts off in the epithelium and passes through the cribriform plate
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of the ethmoid bone [5]. These nerve fibers connect the olfactory epithelium of the nasal cavity to
the olfactory bulbs of the brain [5]. Figure 1 shows the pathway of an electrical signal from the
odor molecule from the environment to the olfactory bulbs.

Figure 1: Path of an odorant molecule. The odor enters through the nostrils into the nasal cavity which is lined with
metabolic enzymes that break down the molecule. The molecular fragments bind to the olfactory nerves which
communicate with the olfactory bulb by passing through the cribriform plate. Once the odor is bound, it will cause the
olfactory nerves to fire, propagating a signal through the olfactory tract. Figure from [52].

OSNs are bipolar structures, containing dendrites, axons and cell bodies. The axons pass
through the cribriform plate and enter the olfactory bulb where the dendrites of OSNs are found
containing hair-like cilia covered with olfactory receptors [6]. These receptors span the plasma
membrane seven times and are involved in various signal transduction pathways. The axons of
OSNs converge in glomeruli in the olfactory bulb.

Singularity in the olfactory system
It has been shown that OSNs express one OR gene per cell, meaning they express ORs in
singularity. Furthermore, each OSN only expresses one functional OR allele, suggesting that OSNs
choose from approximately two thousand alleles [7]. This mechanism of expression is referred to
as “singular expression” [8]. Singular expression has two main defining characteristics:
8

“monogenic expression”, the ability of expressing only one gene, and “monoallelic expression”,
the ability of expressing only one allele [7,9].
One of the biggest mysteries of olfaction is understanding how singular expression arises.
It has been observed that OSNs expressing the same type of OR are scattered throughout a
restricted area of the olfactory epithelium of the nasal cavity, commonly known as a “zone”.
Despite the neurons being scattered, the axons of OSNs expressing the same receptor converge
into a specific glomerulus [7].
As soon as the OSN has chosen an OR to express, it is considered to have “locked in
choice” [10]. It is critical for an OSN to express a singular functional OR allele in order to be able
to mature. Once the choice has been made, the OSN will express only that receptor for the rest of
its lifetime., There are several theories published, which try to explain the phenomena of singular
gene choice.

Possible Model
In order for an OR to be chosen to be expressed in singularity, a series of cascade events
must take place: First, a gene must be transcribed into an mRNA strand. Second, the mRNA strand
must then be translated into an OR protein. Finally, there is suggestive data that the OR needs to
be transported to the plasma membrane. This last point is difficult to prove as a receptor that fails
to traffic to the plasma membrane will lead to the death of the OSN. Singularity can be regulated
at any of these points.
Sometimes, the chosen OR allele does not function correctly. In this case, the OSN is able
to choose again, expressing a second OR allele. It is still uncertain how the OSN “knows” which
allele is functional, and which is non-functional. There are various different hypotheses trying to
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explain this phenomenon. One of the more common hypothesis states that the establishment of a
singular functional OR is due to a GPCR signaling event which happens through adenylyl cyclase
3 (Adcy3) [11]. These studies show that in order for mature OSNs to express a single OR, or to
fully lock in choice, it is required that a cAMP-dependent signaling cascade be activated through
Adcy3 [11]. It has also been suggested that Adcy3 plays an important role in establishing
singularity through a three-node signaling cascade including a sensor for OR expression and a
transmitter for OR feedback [12]. This Adcy3 cascade allows for the OR to be locked in, stabilizing
the singular expression of that OR while also preventing other OR alleles from being transcribed
[12].
This model suggests that singularity is established through an OR-driven feedback loop, as
seen in Figure 2. Before choice, all OR genes are in a silenced state [13]. Lysine-specific histone
demethylase 1A (LSD1), a protein, starts activating a specific OR gene by derepressing it [13].
Once the OR gene is activated, OR mRNA strands become transcribed and translation of the OR
begins in the endoplasmic reticulum. This drives an unfolded protein response (UPR) which
activates the protein kinase RNA-like endoplasmic reticulum kinase (PERK) signaling pathway.
This in turn, phosphorylates eIF2a, a translation initiation factor, leading to the production of the
nuclear isoform of ATF5, a transcription factor and directs transcription of Adcy3 that negatively
regulates LSD1, ultimately leading to singular expression of one OR allele.
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Figure 2: OR-driven feedback loop. Genes start off in a silenced state. LSD1 activates genes, which start producing
mRNA. When the mRNA gets translated, the PERK pathway gets activated, phosphorylating eIF2a and producing
nuclear ATF5. This transcription factor leads to production of Adcy3 protein, which inactivates LSD1. Figure from:
[54].

However, there have been several studies which show that even under conditions where
Adcy3 was knocked out, OSNs expressing a singular OR was still observed [14]. There are two
main classes of OSNs in the nasal cavity – Adcy3 dependent and Adcy3 independent [14]. OSNs
expressing receptors from M71, P2 or MOR23 genes contain very low levels of Adcy3, indicating
that it not required in order for OSNs to express an OR in singularity [14]. This contradicts the
hypothesis that Adcy3 is needed for determining singular expression in olfactory neurons. In
addition, Adcy3 has been found to be a late marker, indicating that singularity is not enforced until
late in the expression process [15]. A more appealing mechanism involves regulating singularity
at the first level of expression – at the mRNA level. This would ensure that the appropriate OR
gets expressed as needed, while also regulating the OR very early on in the expression process.
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Evidence for mRNA model
Various different experiments have been conducted that attempted to understand how
singularity is achieved. It has been noticed that in order for an OSN to lock in choice, the mRNA
coding for the OR needs to come from an DNA portion containing both an OR promoter and an
OR protein [10]. However, when there is an OR promoter associated with a non-OR cytosolic
protein, the cell will not be able to lock in choice [10]. There has also been evidence suggesting
that the opposite is also true, if there is an OR protein associated with a non-OR promoter, the cell
also will not lock in choice [16].
Mature OSNs organize themselves in glomeruli in the bulb. The glomerular positions of
the OSNs are not pre-determined [10]. During development, it is critical that mature OSNs express
a single OR and coalesce into a glomerulus [7]. If one allele is knocked-out, the cells are able to
now co-express this failed first choice and a second OR allele, which now rescues OSN function
[10]. This is known as an OR protein null allele or delOR allele [10]. delOR alleles delete the
feedback function of the OR protein, leaving the promoter intact [10]. It is critical for an OSN to
express one functional OR allele, otherwise it will die [10].
In order for functional expression of an OR protein, its OR promoter must have a functional
homeodomain site (to which the HLH protein binds) as well as a functional O/E site, both of which
act as transcription factors [16]. The cooperative interactions between these proteins is what
ensures that the OSN will properly express an OR in singularity [16]. A true non-functional OR
allele has no OR promoter [16].
An unusual finding has shown that an OR protein expressed from a non-OR promoter will
not lock in choice [16]. This was shown with the pan-neuronal transcription factor, OE2, was used
to drive OR M71 protein expression [16]. The M71 OR was transcribed and translated into a
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functional protein [16]. However, this OR protein expression did not trigger singularity [16]. These
findings suggest that there is something special about the OR promoter vs non-OR promoter that
allows the OR mRNA to be recognized by the OR choice machinery. Perhaps the mRNA from an
OR promoter is targeted in some way creating a specific signature during OR mRNA translation.
I will refer to this signature as a tag.
Many mRNA strands transcribed in a given cell are vastly different from each other due to
differences in tagging. This tagging is facilitated by export proteins found in the nucleoplasm and
some that are found in the cytoplasm. mRNA strands are often tagged by obtaining chemical
modifications on their nucleotide sequences, allowing them to be different from each other. These
modifications serve different purposes, including to prevent the mRNA strand from being
degraded. I will discuss different known mRNA modifications later in this thesis.
In OSNs, mRNA tagging of OR genes could be a way to communicate to the cell that the
mRNA strand is coming from a particular part of the nucleus, containing an OR promoter. This
can either be done through nucleotide modifications or through the recruitment of a protein on the
strand. We believe that the ORs which end up being expressed in singularity could come from
mRNA that is tagged, indicating that the singular gene choice has occurred within the cell.

What is mRNA
Heteronuclear or pre-mRNA, aka hnRNA, is a molecule which is synthesized during
transcription inside the nucleus of a cell. It consists of a single strand of nucleotides which
correspond to specific regions within a gene. One important enzyme involved in transcription is
RNA polymerase II (RNA Pol II). This enzyme, along with other transcription factors, is able to
attach to an unwound DNA strand and generate a primary transcript RNA strand from a particular
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section of the genome. This pre-mRNA strand is then processed, and all the introns, are removed
from the strand, leaving behind the 5’ and 3’ UTRs as well as protein-coding regions which are
spliced back together.
After the pre-mRNA strand is spliced, it is capped on the 5’ end in order to prevent it from
degrading once it leaves the nucleus. The pre-mRNA also receives a 3’ polyadenine tail, poly(A)
tail, which consists of a long strand of adenine nucleotides which facilitate its export from the
nucleus as well as its translation. The poly(A) tail also prevents the mRNA from getting degraded
outside the nucleus. Figure 3 shows transcription, mRNA processing and export out of the nucleus.

Figure 3: Transcription, processing and export of mRNA. RNA polymerase II binds to the DNA strand and starts
unwinding it, allowing the pre-mRNA to be synthesized. The pre-mRNA then undergoes a series of processing steps,
including the addition of a 5’ cap, a poly(A) tail and splicing of introns. The mRNA is now able to exit the nucleus
and enter the cytoplasm where it will get translated. Figure from [53].
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Difference between mRNA from an OR promoter versus non-OR promoter
In the olfactory system, overexpression of an OR protein from the OE2 promoter does not
lead to feedback to control its own expression. One possibility why this might happen is that the
OSN can differentiate between a OR mRNA transcript that comes from an OR promoter versus an
mRNA transcript that comes from a non-OR promoter. Differential tagging would lead to two
different outcomes: OR promoter driven transcripts would produce a feedback upon protein
translation in the ER and those that do not contain this tag would be treated like other GPCRs that
the OSN produces. One possible way that an OSN can achieve this is by tagging the mRNA as
part of the process of singular gene expression.
The cell can use several possible mechanisms to tag mRNA. One way might be that a
protein associates with the mRNA transcript before it leaves the nucleus. The tagged transcript is
then translated and transported into the ER because ORs are transmembrane proteins. This can be
accomplished by having a protein in either the nucleus or in the cytoplasm bind to a particular
mRNA sequence on the 5’ UTR, 3’UTR or coding sequences, allowing the cell to recognize that
the mRNA originated from a singular choice gene promoter.
The second possible way the mRNA might be marked is through the 5’ cap. It has been
shown that there are chemical modifications on the 5’ cap of mRNA strands but it is still unclear
as to what role they play. These chemical modifications, found in the mRNA nucleotide bases,
may serve as a way of allowing the cell to recognize that the encoded OR must be expressed in
singularity.
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Modifications on the mRNA strand
As previously mentioned, the pre-mRNA strand is processed in several different ways before it is
able to leave the nucleus.
For most RNA Pol II dependent mRNA transcripts, a nucleotide on the 5’ end is also
modified. This is known as the 5’cap. This is another important step to ensure that the mRNA
strand successfully undergoes translation. The 5’cap consists of a 5’ to 5’ triphosphate linkage
connecting a guanine nucleotide to the mRNA strand [17]. Figure 4 shows the structure of Cap1,
one of the most common caps found to be associated with mRNA strands of mammalian cells. I
will discuss different cap structures in the next section.

Figure 4: Cap1 structure. Cap1 modification is the most common cap found in mRNA strands of mammalian cells.
The 7- methylated guanosine is linked to the transcribed nucleotide via a triphosphate bridge and a methyl a group is
added to the first transcribed nucleotide. Figure from: [34].

Removal of introns and splicing together of exons is another common modification that
must take place in mRNA strands translated from OR genes [18]. Introns are sections of RNA that
do not end up in the mRNA. The splicing reaction is catalyzed by a complex of small ribonuclear
proteins known as a spliceosome [18]. The pre-mRNA strands are able to be spliced in different
ways in order to produce multiple mature mRNAs that encode different proteins. This is a process
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known as alternative splicing [18]. A small portion of the mRNA strand contains the coding region
while the rest is the non-coding region, which are referred to as the untranslated regions. These
untranslated regions are important for the regulation of the activity of the mRNA strand [18]. There
are some cases in which the entire mRNA strand is composed entirely of untranslated regions.
These mRNAs are known as non-coding RNAs and they are often used for regulatory purposes in
the cell [18].
The addition of the poly(A) tail, another modification the pre-mRNA strand undergoes,
occurs as soon as transcription ends. The poly(A) tail serves multiple purposes for the mRNA
strand, the first being to ensure that transcription is successfully terminated [19]. It also prevents
the mRNA strand from being degraded in the cytoplasm, aids in the transport of the strand outside
of the nucleus and it also assists in the translation process [19]. This process involves cleavage and
adenylation reactions, both which occur near a polyadenylation signal sequence which is found
next to the 3’ end of the mRNA strand [19]. The addition of the poly(A) tail is catalyzed by a
processive polyadenylation complex which involves six different proteins [20, 21]. Some mRNA
strands do not have a poly(A) tail, and these include the replication dependent histone mRNAs
[22].

Types of mRNA caps
There are various different ways in which the mRNA can be additionally modified. The
first way is through modification of specialized nucleotides along the mRNA strand. Cap0 also
contains a methylated guanosine (m7G) on the N-7th nucleotide position, which is connected to the
mRNA through a 5’ to 5’ triphosphate linkage, as shown in Figure 5. This cap is often abbreviated
as m7G, which stands for 7-methylguanylate, indicating that the methyl group is attached to the
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guanosine on the 7th position, a reaction performed by a capping enzyme complex [23]. This
modification happens during transcription and it serves as a way for RNA proteins to bind to the
mRNA strand [24]. Many different cap binding proteins are able to interact with mRNA caps.
Because m7G is a nucleotide specific modification, the proteins that bind to this cap must also be
nucleotide specific [25]. These Cap0 modifications are difficult to identify during routine mRNA
sequencing.
It is possible that during transcription, the m7G modification gets incorporated into the
mRNA and a singular transcription specific protein binds to the modification during transcription,
allowing the cell to recognize that the OR should be expressed in singularity. This is an abundant
modification that is often observed in 5’ caps [26]. Enzymes involved in cap modifications are
specific to caps only. It is unlikely that enzymes that modify internal mRNA residues are the same
enzymes that modify the 5’ caps [27]. Further modifications to the mRNA nucleotides could also
be co-transcriptional during OR gene expression.
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Figure 5: Different types of mRNA cap structures. Structural differences between some of the most abundant
mRNA caps. Figure from: [51].

Although the Cap0 m7G modification is one of the most common modifications found on
mRNA strands, there are other further modifications that can occur in eukaryotes as well as viruses.
The addition of Cap1, another very common cap, is another possible modification. It is very similar
in structure as Cap0 but it contains an additional methylation on the 2’-hydroxy group of the first
ribose sugar [28]. Furthermore, Cap2 modifications contain methylations on the 2’-hydroxy group
on the first and second ribose sugars [28]. Figure 5 shows different 5’ cap structures found in
mRNA. It is currently still unclear whether Cap0 is required to be present in order for the
modification to occur at the first transcribed nucleotide in Cap1 [29]. Studies show that mRNA
transcripts containing Cap0 are more rapidly degraded compared to mRNA transcripts containing
Cap1 [30]. This suggests that the 2’-O-methylation found in Cap1 modifications serves an
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important role in preventing the degradation of mRNA strands [30]. The true function of a Cap1
modification is still largely unknown [29]. It has been observed that Cap1 does not have a large
effect on ribosome recruitment [29]. One difference that was noticed between Cap1 and Cap2
modifications is that Cap1 methylation is believed to be nuclear while Cap2 methylation on the
second transcribed nucleotide is in the cytoplasm [31]. It has also been shown that the removal of
the methyl group in Cap1 does not have any significant effect on mRNA translation; however, it
is believed that removal of both methyl groups in Cap1 and Cap2 results in a change in mRNA
activity [29].
Viral mRNA caps have similar modifications like the ones described above. Viral mRNAs
containing adenosine as the first transcribed nucleotide, are often observed to be associated with a
Cap1 structure [32]. Similarly, there are variations of Cap2 in viral mRNAs as well. Other
modifications that have been studied in viral mRNAs are non-methylated guanosine caps (GpppN)
and other caps containing multiple methylations, including di- and tri-methylated guanosine caps
[33]. Other small mRNAs contain a very simple modified cap structure which includes a gammaphosphate methylation on the unprocessed 5’ triphosphate (mPPPN) [33].
Some bacterial small mRNAs have an even greater diversity of modified caps, including
nicotinamide adenine dinucleotide (NAD) and coenzyme A (CoA) [33]. NAD caps are also found
on human mRNAs and non-coding mRNAs [33]. Other cap structures have been observed in vitro
experiments, including flavin adenine dinucleotide (FAD), uridine diphosphate glucose (UDPGlc) and uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) [33]. One possible role
metabolite 5’ caps serve is regulating gene expression. It has been shown that an NAD cap
influences RNA stability and turnover [33].
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Cap binding complexes
There are many different proteins that interact with the mRNA cap and facilitate regulation.
The two major cap binding complexes are CBC (Cap Binding Complex) and eIF4F [34]. The most
abundant form of CBC is NCBP1-NCBP2 [23]. However, it has also been noticed that a lesser
abundant form of the complex, NCBP1-NCPB3, also interacts with the mRNA strand [35]. This
alternative binding complex has been shown to play an important role in immune response during
viral infections [36].
The second cap binding complex that is found abundantly in cells is eIF4E, a eukaryotic
initiation factor. This complex is composed of eIF4E2 and eIF4E3 subunits [37]. Both of these
subunits have been shown to have lower affinities for the cap structure compared to eIF4E [38].
eIF4E2 has been noticed to form under hypoxic conditions, when eIF4E is inhibited [34]. It has
been shown that overexpression of eIF4E3 has been linked to a decrease in the expression of
oncogenic proteins, indicating that it acts as a tumor suppressor [39]. Both of these units interact
with m7G cap, however neither capping structures have been extensively researched [34].
There are other cap binding proteins that have been newly identified. LARP1 (La-related
Protein 1) binds to the cap in order to stabilize transcripts [40]. Once LARP1 is bound to the cap,
it prevents the binding of eIF4E protein [41]. Other proteins, such as Pumilio 2, have also been
found to compete with eIF4E and inhibit translation [42]. It is clear that there are a variety of
different proteins interacting with cap structures of mRNA.

How does the cap get added?
Several different enzymes catalyze the mRNA capping reaction. RNA guanylyltransferase
and 5’ phosphatase (RNGTT), a capping enzyme, catalyzes the initial reaction of the addition of
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the guanosine cap [43]. The two catalytic sites, triphosphotase and guanylyltransferase interact
with the first nucleotide of the mRNA, the 5’ triphosphate (ppp(5’) X), in order to add the first
cap, creating G(5’)ppp(5’)X [44]. RNA guanine 7-methyltransferase (RNMT) catalyzes the
reaction of the addition of a methyl group on the N-7 position of the guanosine cap added by
RNGTT [45]. RNMT also contains an activating subunit, RNMT-activating miniprotein (RAM),
which allows for the stabilization of the structure and positioning of the RNMT lobe [46]. Most of
these capping enzymes are present in the nucleus, however RNMT-RAM can also be found in the
cytoplasm [47]. Another modification that takes place on the mRNA strand of mammalian cells is
the addition of a methyl group on the O-2 position of the ribose of the first and second nucleotides
is methylated. This reaction is catalyzed by Cap Methyltransferase 1 and Cap Methyltransferase 2
(CMTR1 and CMTR2) [29, 49]. There have been no other enzymes found to be involved in other
cap methylations [49].
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Aim

It is a mystery how OSNs come to express ORs in singularity. There are different theories
that try to explain this phenomenon; however, most are disproved by counter studies. In this
theoretical thesis, I will be describing a series of experiments designed to better our understanding
of the structure of mRNA 5’ caps and of the first few nucleotides of the 5’ UTR. In this study, I
wanted to determine whether or not there are modifications on the 5’ cap of mRNA strands from
ORs. These hypothetical experiments were not finalized. I was able to complete only the first stage
of the experiments due to the COVID-19 lockdown.
There will be three types of results presented and discussed in this study: the possibility of
obtaining a positive result, a negative result, or an inconclusive result.
My hypothesis is that 5’cap modifications exist which in turn drive singularity.
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Experimental Overview

In this experimental design, we plan to extract OR1A1 mRNA from mouse olfactory
epithelium and analyze it using liquid chromatography mass spectroscopy (LC-MS) to look for
modifications on the 5’ cap and first few nucleotides of the 5’ UTR. First, we will obtain in vitro
synthesized RNA from Integrated DNA Technologies (IDT). Two types of strands will be ordered,
one with the 5’ UTR of the M71 OR and one with the OMP 5’UTR such that they serve as controls.
OMP is a highly expressed gene that is not subject to singular gene choice and serves as a control.
We will run these controls both capped and uncapped on the LC-MS, to understand what kind of
peaks that can be observed. We will use the uncapped LC-MS graph to set the zero point for an
uncapped sample.
In order to prepare the controls to be run on the LC-MS, we will order biotinylated probes,
containing several DNA nucleotides. We will anneal the probe to the mRNA control strand then
bind the complex to streptavidin beads. We will then cleave the complex with RNaseH, an enzyme
that degrades DNA/RNA hybrids, and elute the remaining portion which will then be analyzed via
LC-MS. The DNA nucleotides are necessary for the RNaseH enzyme to properly cleave the
annealed strands.
After running both controls on the LC-MS, we will obtain extracted OR1A1 mRNA and
OMP mRNA from mouse olfactory epithelium. This will be extracted from MouSensor, a mouse
line that contains amplified OR expression, allowing us to be able extract a lot more mRNA for a
single OR than if we were to use a normal mouse. We will be using OR1A1 mRNA because it
contains the same 5’UTR as the M71. We will run this experiment exactly like we ran the control
strands.

24

The figures presented in the next section are theoretical. Previous studies have shown that
the uncapped region is the lightest in weight followed by cap 1. In this theoretical thesis, we have
assumed the cap with a novel modification to be heavier than either cap 0 or cap 1. The figures are
a hypothetical representation of our three possible outcomes. These figures are used to strictly
show one possible version of our results. Using published data and figures, we have created figures
to match our different anticipated outcomes [55].
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Results

As mentioned in the aim section, we will be presenting three different possible outcomes.
Our goal is to determine whether or not there exist modifications on the 5’ cap and the first few
nucleotides on the 5’ UTR of mRNA strands extracted from mRNA coding for ORs in olfactory
neurons. For each possible outcome, we will discuss the implications it would have on the overall
goals of the experiment.
Before testing the mRNA extracted from the olfactory epithelium, we tested the protocol
on synthesized mRNA strands which we obtained from IDT. These control strands were both
capped and uncapped at the 5’ end. Running the protocol on both strands would result in a better
understanding of what we would expect our results to look like.
In order to analyze the mRNA 5’ cap, we wanted to use an approach described by Lapham
and Crothers to cleave the strand at a designated location [50]. The mRNA strand would be
annealed to a cleavage probe which consisted of 25 base pairs (20 RNA nucleotides and 5 DNA
nucleotides), the optimal number of base pairs necessary to ensure high specificity annealing and
subsequent RNAseH binding. We decided to use a highly specific probe in order to ensure that it
will bind to only our desired mRNA strand. The probe would anneal to the first 25 nucleotides of
the strand. It is crucial that at least five bases on the 3’ end of the probe are DNA nucleotides in
order to allow RNase H to successfully recognize the cleavage site. The 5’ end of the probe will
be biotin-tagged in order to bind to the streptavidin beads and allow the capture of the cleaved
fragment. Figures 6A and 6B show the protocol that will be used to isolate the 5’ caps of the two
control mRNA strands. The fragments would be eluted and run on an LC-MS. Because different
caps contain different masses, we would be able to easily determine whether or not the isolated
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caps contain modifications. All caps would be run on a total ion chromatogram, the liquid
chromatography and an electrospray MS.
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Figure 6: Procedure for isolating the 5’ cap fragment of mRNA control strands. Isolated fragments will be sent
out for LC-MS analysis. The portion of the probe highlighted in turquoise represents the DNA nucleotides. The portion
of the mRNA strand highlighted in yellow represents the portion which was annealed to the biotin labeled probe. The
purple sphere on the left-hand side of the figure represents the streptavidin magnetic bead to which the biotin tag
binds. The blue arrow shows where the RNase H will cleave the RNA/DNA hybrid. (A) Shows the protocol for the
mRNA containing an M71 UTR region. (B) Shows the protocol for the mRNA containing an OMP 5’UTR.
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Once the control strands are run on the protocol, we have to test mRNA extracted from the
olfactory epithelium. We are able to extract about 40μg of total RNA from the mouse epithelium
of one animal. Roughly, 5% of total RNA is mRNA. This suggests that we are able to extract about
2μg of mRNA per animal. About 1% of the total mRNA contains M71 or OMP 5’UTR, indicating
about 0.2μg or 200ng. In order for the LC-MS to properly read our mRNA sample, we would need
to obtain mRNA extracted from the olfactory epithelium of 10 animals.

There is no novel modification on the mRNA cap other than Cap0 or Cap1
The first possible outcome for this experiment is that there is no novel modification on the
mRNA 5’ fragment isolated from the sample. As seen in Figure 7A and 7B, the sample would be
analyzed on the LC-MS and the peaks that appeared would be indicative of a modification similar
to the Cap1 5’ modification (and/or Cap0, not shown). This would suggest that the fragments
isolated from OR mRNA strands are not modified in a novel way. They would peak at exactly the
same place as Cap 1 (and/or Cap0, not shown) normally does.
In this possible outcome, there appears to be no difference in the naturally occurring mRNA
caps and the mRNA cap we would isolate. Figure 7A shows how the total ion chromatogram
might look for the isolated fragments. The column we will use is a 1-3mm microbore column,
which will separate our sample based on size. As seen in this graph, there is a small amount of the
eluted mRNA is uncapped – a naturally occurring phenomenon. These fragments tend to come up
sooner on the total ion chromatogram since they are smaller in size and elute first. The majority of
mRNA is capped with Cap1 (and/or Cap0, not shown). This cap will come up slightly later on the
total ion chromatogram since it is heavier than the uncapped mRNA and will elute slower.
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Figure 7: LC-MS of sample with no novel modification on mRNA cap. Mass spectrometry of a sample of isolated
cap fragments from mRNA strands extracted from olfactory neurons. (A) The total ion chromatogram of the sample.
(B) electrospray mass spectra of the sample. Only hypothetical Cap1 patterns are shown. Cap0 patterns are also a
possibility. Adapted from: [55].

The sample would then be run on an electrospray mass spectrum in order to better observe
how the sample separated. Figure 7B shows how the fragments might separate once the analysis
would be completed, based on the mass/charge ratio. As seen from Figure 7B, fragments that are
higher in mass, such as Cap1 (and/or Cap0, not shown), have a lower mass/charge ratio than
fragments of lighter mass. Although Cap1 fragments are higher in mass, they are also more
charged, meaning their mass/charge ratio will be lower than the ratio for the uncapped region. This
can be observed in the electrospray mass spectrum graph. This data would be consistent with the
total ion chromatogram findings, since both indicate that Cap1 (and/or Cap0, not shown) has a
higher mass overall. The uncapped portion of the mRNA would appear to peak slightly later than
Cap1 on the electrospray mass spectrum, indicating it has a lower mass and is more heavily
charged, allowing it to be propelled at greater speeds through the mass spectrum. Again, this would
be consistent with our findings from the total ion chromatogram since the uncapped region peaked
sooner than the Cap1 region.
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There is a modification on the mRNA cap
Another potential outcome for this experiment might be that there exists a novel
modification on the mRNA 5’ cap fragment which will be isolated from OSNs. This would result
in a completely different peak than normally observed for Cap1 or Cap0, suggesting that the mass
of the isolated 5’ cap is different than that of any known cap. This would be seen as a completely
different fragmentation pattern expressed on the LC-MS graph compared to normal Cap1 or Cap0
patterns. As seen in Figure 8A, the modified cap would elute much later than the uncapped
fragment. Having a higher mass is indicative of modifications on the cap. The proteins that make
up the 5’ cap contribute significantly to the overall mass of the cap, putting it further on the
electrospray mass spectra.
As Figure 8A suggests, the uncapped region of mRNA would appear very early on in the
total ion chromatogram, indicating that it would have a lower overall mass compared to other
fragments. A size exclusion column would be used to separate the fragments based on size. Also
observed in Figure 8A is a high peak coming up late on the chromatograph, at a position that we
would not normally expect any known cap to come up. This would indicate that the mass of the
modified cap is significantly higher than the mass of the mRNA caps we are familiar with.
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Figure 8: LC-MS of sample with novel modification on mRNA cap. Mass spectrometry of a sample of isolated
cap fragments from mRNA strands extracted from olfactory neurons. (A) The total ion chromatogram of the sample.
(B) electrospray mass spectra of the sample. Adapted from: [55].

The sample would also be run on an electrospray mass spectrometer in order to generate
more information about the nature of the cap. As observed in Figure 8B, the modified cap has a
significantly higher mass and is therefore more charged. This indicated that it has a lower
mass/charge ratio. The fragmentation pattern of the mRNA uncapped 5’ coding region has a higher
mass/charge ratio because it is lower in mass and not as heavily charged. This would be consistent
with the findings from the chromatogram. The heavier fragments appear to elute late on the total
ion chromatogram because they are heavier. When run on the mass spectrum, they contain a lower
mass/charge ratio.

It is not clear whether there is a novel modification on the mRNA cap
The last possible outcome for this experiment would be if the results are inconclusive,
meaning we are not entirely certain whether or not there exist unique cap modifications on mRNA
strands coding for ORs. One way this might be observed is if there exist different peaks that come
up on the LC-MS analysis, as shown in Figure 9. The graphs presented in Figure 9 indicate that
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some of the isolated sample would be uncapped, some capped with Cap1 (and/or Cap 0, not shown)
and some capped with a completely different cap. Because there would be different peaks present,
it would not be certain if the small amount of mRNA consisting of a modified cap is enough for
effective communication to the cell. In this regard, it is unclear if all the OR mRNA caps would
need to be a uniform structure.
This ambiguity in the LC-MS results might appear as three distinct peaks on the LC-MS,
one indicating the uncapped fragment, one coming up where we would expect Cap 1 (and/or Cap0,
not shown) to appear and a new peak, one which we have never seen before, as seen in Figure 9A.
These three distinct fragments would separate based on differences in mass. In the total ion
chromatogram, we would use a size exclusion column, allowing the fragments to separate based
on mass. Fragments that have a lower mass tend to appear sooner on the chromatogram while
fragments that have a higher mass appear later. As seen in Figure 9A, the new peak appears late
in the chromatograph, suggesting that the fragment would have a higher mass compared to other
fragments isolated from the sample.
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Figure 9: LC-MS of sample with mixture of mRNA caps. Mass spectrometry of a sample of isolated cap fragments
from mRNA strands extracted from olfactory neurons. (A) The total ion chromatogram of the sample. (B) electrospray
mass spectra of the sample. Only hypothetical Cap1 patterns are shown. Cap0 patterns are also a possibility. Adapted
from: [55].

Figure 9B shows what the sample might look like after being run on an electrospray mass
spectrum. The different isolated fragments from the sample appear to have different mass/charge
ratios. Fragments that are higher in mass have a lower mass/charge ratio while fragments that are
lower in mass have a higher mass/charge ratio. As seen from this electrospray mass spectrum, it is
clear that this sample contains fragments with a modified cap which have a lower mass/charge
ratio. The Cap1 (and/or Cap0, not shown) fragmentation pattern appears between the modified cap
fragmentation pattern and the uncapped fragmentation pattern on the electrospray mass spectrum.
This would indicate that the modified cap fragment, although it is higher in mass, is also more
charged, resulting in a very low mass/charge ratio. The Cap1 (and/or Cap0) fragment is lighter
than the modified cap fragment and it contains a lower charge than the modified cap, resulting in
a higher mass/charge ratio in comparison to the modified cap. The uncapped fragment is the
lightest in weight out of all the fragments, resulting in the least charge. This would indicate in
having the highest mass/charge ratio out of all the fragments found in this sample.
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Discussion

Our experiments were intended on better understanding how singularity is achieved in
olfactory neurons. It has been shown that in order for an OSN to reach maturity, the neuron must
express only one odorant receptor. This expression of a singular OR is still not entirely understood.
There are several theories about how this might be achieved, however none have been proven.
We believe that the reason why singular expression is observed in OSNs could be because
the mRNA encoding a particular OR is somehow marked, allowing the cell to recognize it. The
marking of the mRNA, we believe, is found on the 5’ cap. The 5’ cap is a modification added to
all mRNA strands which helps prevent degradation once the strand is in the cytoplasm. Several
different types of mRNA caps exist, all containing different modifications. We are not sure what
purposes the different modifications serve for the mRNA. It is possible that in order for an OR to
be expressed and signal singular gene choice has occurred, the mRNA cap is marked with a
specific modification – one that does not exist for non-OR OSN expressed mRNA caps.
In order to test this hypothesis, we first planned on testing synthesized RNAs ordered from
IDT to show that the experimental protocol could work. We initially tested two types of controls,
capped mRNA strands and uncapped mRNA strands. This allowed us to make any changes to the
protocol as needed, before testing mRNA strands extracted from the olfactory epithelium.
After we would test the control samples, we would extract OR1A1 mRNA and control
OMP mRNA from mouse olfactory epithelium and isolate the caps of the mRNA strands present.
To do so, we designed a biotinylated probe which consisted of 25 base pairs, 20 of which were
RNA nucleotides and 5 which were DNA nucleotides, as seen in Figure 6. This probe, which
contained specificity for the 5’ end of the mRNA strand, would anneal to the mRNA strand. The
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hybrid would be attached to streptavidin beads and then cleaved with RNase H. The fragment that
would remain attached to the streptavidin beads should contain the 5’ UTR of the mRNA strand.
After the fragment would be eluted, we would be able to analyze it using LC-MS.
After the 5’ cap is isolated and analyzed using LC-MS, we expect to get one of three
possible results: negative, positive, or inconclusive. Each of these results and its consequences will
be described in detail.

Negative Result
A negative result would suggest that the mRNA cap is not marked in any novel fashion, to
signal to the cell that it should express a particular OR in singularity. We can conclude that the cell
uses another way to ensure signal singular gene choice has occurred. It is possible that other parts
of the mRNA are modified before it leaves the nucleus. However, because the mRNA strand is
very large, we are not able to analyze it as a whole. Therefore, in order to ensure that there are no
modifications anywhere on the strand, we would have to isolate different fragments and analyze
them independently. It is also possible that there are modifications on the 3’ poly(A) tail, a location
which we did not isolate in this experiment. These could be studied using different biotinylated
oligos.
In order to confirm that there are in fact, no novel modifications on the mRNA strand, we
would have to analyze the mRNA strand in more detail. It is possible that we would not be able to
find modifications on the strand at all. If this is the case, then we can conclude that the mRNA
does not get marked and the cell utilizes other means of determining which OR gene was subject
to the singular choice machinery. This means that we would need to look at other possible
mechanisms the cell might use in order to choose which OR to express. The simplest mechanism
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would be a co-transcriptional event where a protein binds to the cap structure during transcription
of the singularly chosen OR gene.

Positive Result
A positive result would indicate that in order for singularity to be achieved, the cell marks
the mRNA in a novel way. This would confirm our hypothesis – in order for the cell to recognize
which OR was subject to singular gene choice, the mRNA must be marked on the 5’ end with a
specific modification. To further this experiment, we would have to look if this novel cap was
specific to OR mRNAs compared to other mRNAs expressed in OSNs. For example, does the
highly expressed OMP mRNA have a different cap structure than a chosen OR?
To better understand how the cell marks the mRNA, we would also have to conduct a series
of experiments which would allow us to understand what part of the cell is responsible for the
modification of the cap. Does the cap get modified in the cytoplasm or the nucleus? Depending on
the place where it gets modified, it can potentially convey a lot of information about the importance
of the cap and the different factors that come into play whenever there is the need to make a choice
of which OR to express. Finally, these modifications can be a result of different linkages on the
5’ cap, different proteins making up the cap, or a combination of the two.

Inconclusive Result
Because the isolated sample would contain a mixture of different caps, we would not be
able to claim with certainty that the modified cap is present in order to communicate to the cell
which OR should be expressed in singularity. Because this sample would contain a mixture of
different cap structures, further questions would arise. Why did some mRNA strands get capped
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with a different cap versus Cap1 or Cap0? In order to better understand this, we would have to
look at different mRNA strands coding different ORs. By isolating their caps, we would run the
same experiment and see if there is a similar pattern.
It is also possible that in order for an OR to be expressed in singularity, only a portion of
the mRNA that is transcribed from an OR promoter and OR coding region would have to be tagged.
This particular ratio of marked/unmarked mRNA might be what drives singularity and what is
being communicated to the cell.
Although this might not be indicative of a modified cap being present in OR mRNA
strands, it would suggest that the OR mRNA strands are slightly different – by being capped with
two different types of caps. This would require further experiments to identify the importance of
the novel cap in a small portion of the sample. It would also be important to understand where
these two different caps are added to the mRNA strand. Are they added in the cytoplasm or the
nucleus? This would further our understanding of why they are capped differently. Other
experiments would consist of analyzing the entire strand of mRNA and look for other
modifications (especially at the 5’ end and the 3’ end). The findings might suggest that there are
capping enzymes that recognize parts of the modified mRNA strand. These modifications could
potentially dictate which strands should get capped differently by enzymes found in the cytoplasm.
Once part of the sample is capped with the novel cap, it could be enough to ensure singular
expression of an OR in the cell.

Future Directions
To better understand how singularity is achieved, the experiments outlined in the above
pages would only scratch the surface of this problem. If the results reveal a novel cap, then we
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would have to understand what proteins are involved in the mRNA capping process. We would
also have to understand the exact nature of the modifications– is it just the cap, the 5’ UTR or is
the strand modified in other places as well?
Another question may arise. If there is an OR promoter and a non-OR coding region, would
the mRNA still get a novel tagged? Would a non-OR promoter expressing an OR protein, as in
OE2 driving M71 mice, receive this novel cap, Cap1 or Cap0?
This experiment was designed to analyze cap structure of mRNA strands encoding ORs
for any modifications that might indicate regulation of singular expression in the olfactory system.
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Methods and Materials

Samples used
In order to test the hypothesis, we wanted to use two different controls. The 5’ UTR of an
M71 strand and the 5’ UTR of an OMP strand, both of which were ordered from Integrated DNA
Technologies, would serve as control samples for this experiment. Both mRNA control strands
were capped using Vaccinia Capping System (Part # M2080S, New England Biolabs, Ipswich,
MA). The capping system adds a 7-methylguanytilated Cap0 to the 5’ end of the RNA strand. The
capping was performed according to the manufacturing protocol. We wanted to test the strands
both capped and uncapped in order to ensure that our methodology worked. After we would test
both controls, we would obtain OR1A1 MouSensor mRNA which would be extracted from mouse
olfactory epithelium. The capping system used on the control strands would not be used on the
mRNA extracted from epithelium.
The 5’ UTR of the control M71 gene ordered from IDT contained the following sequence
5’ to 3’:
rArGrUrCrArUrArUrUrArUrArUrCrArCrCrUrUrUrCrCrArArArUrGrArCrArArUrCrUrCrCrUr
UrUrUrCrCrGrGrArCrUrArGrArCrUrGrGrGrCrUrCrUrUrUrArArGrUrArArArUrUrUrUrGrUr
GrGrUrGrUrArUrArCrArCrArUrCrUrGrCrArUrArCrUrUrCrUrArGrArArUrUrUrArCrUrGrAr
ArUrArUrUrGrArArGrCrCrArCrArGrArCrArUrUrGrCrCrUrGrArArGrUrUrUrCrArUrUrUrGr
ArGrArCrGrCrUrGrUrUrUrCrArUrUrUrCrCrUrUrCrArGrCrArCrArG. The bases with a
preceding “r” are RNA bases.
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The 5’ UTR of the control OMP gene ordered from IDT contained the following
sequence 5’ to 3’:
rArCrTrTrGrArTrTrCrCrCrTrGrArCrGrTrCrTrGrTrGrGrCrArGrTrGrGrTrGrGrCrArGrTrGrGr
CrArArCrArGrCrTrGrTrArGrCrArCrTrTrGrGrGrCrC.
The RNase H cleavage probes were also ordered from Integrated DNA Technologies. The
cleavage probe for the M71 gene contained the following sequence 5’ to 3’:
TTGGArArArGrGrUrGrArUrArUrArArUrArUrGrArCrU/3BioTEG/. The bases with a preceding
“r” are RNA bases while those that have no lower-case letter prefix are DNA bases.
The cleavage probe for the OMP gene contained the following sequence 5’ to 3’:
TGCCArCrArGrArCrGrUrCrArGrGrGrArArUrCrArArGrU/3BioTEG/. Both of the RNase H
cleavage probes were used both on the control samples as well as on the OR1A1 MouSensor
mRNA.
Both the RNase H and the RNase H reaction buffer were purchased from New England
Biolabs (Part # M0297S, Ipswich, MA). The streptavidin-coated magnetic beads were purchased
from Invitrogen (Part # 65001, Life Technologies, Grand Island, NY) and were prepared according
to manufacturer’s protocols.

Annealing probe and sample, binding to beads
To make sure that all the mRNA samples were bound to a biotin cleavage probe, a 5:1
excess probe would be used. The annealing reaction would be done in 120μL of RNase H reaction
buffer. The mixture should consist of a 12μL RNase H reaction buffer (10x), 103μL mRNA
(100pmol), and 5μL RNase H probe (500pmol). These ratios may be used to ensure that the RNase
H reaction buffer is at a final concentration of 1x. This mixture would then be placed in a
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thermocycler to make sure that the annealing between the probe and the mRNA strand takes place.
The thermocycler should be programmed to start off at 95°C for 5 minutes, then decrease the
temperature at 2-minute intervals to 65°C, 55°C, 40°C, and lastly 22°C.
For the immobilization of the beads, 100μL may be used out of the total 2mg/mL which
should be prepared according to the protocol. To remove the storing buffer (0.1M NaCl), the beads
should be centrifuged at 15,000xg for 5 min. The 120μL of the mixture prepared, containing the
annealed mRNA and probe, would be added to the streptavidin beads, then incubated at room
temperature for 30 minutes with gentle rotation.

RNaseH cleavage and elution
After the 30 min incubation period, the 10μL of RNase H would be added to the beads and
mixed by pipetting up and down. This mixture should be then incubated at 37°C for 3 hours. After
the incubation period, the beads are supposed to be condensed using a magnet while the
supernatant is removed and discarded without touching the beads.
Beads should then be washed with 100μL of washing buffer by pipetting up and down. The
washing buffer is supposed to be composed of 5mM Tris-HCl, pH 7.5; 0.5mM EDTA; and 1M
NaCl. Supernatant should be removed after samples are placed on a magnet for 2 minutes. This
washing procedure is typically done three times, followed by three washes with distilled water (to
remove excess salt).
The distilled water is removed and discarded from the beads. 100μL of 75% methanol
(heated to 80°C) is then added to the beads in order to remove the bound mRNA. The mixture
should then be heated to 80°C on a hot plate for 3 min and placed on a magnet for 3 min.
Supernatant is collected and dried to 10μL at room temperature with evaporative centrifuge (for
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45 min). Sample should be resuspended in 50μL of 100μM EDTA/1% MeOH to prepare it for LCMS analysis.

Analysis of sample using LC-MS
Analysis of the cleaved fragment was to be done by Dr. Barney Yoo at Hunter College
CUNY. However, we did not officially get to this step.
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